Literature DB >> 26624583

Atherosclerosis and Liver Function Tests in Coronary Angiography Patients.

Y C Doganer1,2, J E Rohrer3, U Aydogan4, D C Agerter3, T Cayci5, C Barcin6.   

Abstract

OBJECTIVE: Elevated aminotransferase levels indicating liver function, even in the normal range, have attracted great concern as potential novel markers of cardiovascular risk assessment. We hypothesized the possibility that liver function test variations in the normal range might be meaningfully associated to coronary artery disease (CAD).
METHOD: Eighty-eight patients were randomly selected from those who underwent coronary angiography from June 2010 to June 2011 after applying to the outpatient cardiology clinic in Gulhane Military Medical Academy. According to the results of angiographies, patients were classified into three groups as normal, non-critical (< 50% involvement in coronaries), and critical (≥ 50% involvement in coronaries). In addition to angiographic intervention, measurements of serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) concentrations, albumin and the other serum parameters were performed in all patients.
RESULTS: The patient groups of CAD were balanced (28 critical cases, 30 non-critical cases and 30 normal cases). Mean age was 51.93 ± 9.3 (range 32-65) years and 19.3 per cent (n = 17) were females. Multiple linear regression analysis of all three liver function tests explained a significant portion of the variance, but adjusted r-squares were small (AST = 0.174, ALT = 0.242, albumin = 0.124). Albumin was significantly higher for patients with critical CAD than for patients with no CAD (beta = 3.205, p = 0.002). Non-critical CAD was not significantly different from no CAD for any of the dependent variables. Mean AST was significantly higher for patients taking aspirin (beta = 0.218, p = 0.049), as was mean ALT (beta = 0.264, p = 0.015).
CONCLUSION: Alanine aminotransferase and AST may not be associated with angiographically determined coronary atherosclerosis. Albumin may be more sensitive to demonstrate the burden of atherosclerosis. These results indicate that the association between the liver function tests and coronary atherosclerosis may be more complex than generally appreciated.

Entities:  

Year:  2015        PMID: 26624583      PMCID: PMC4909063          DOI: 10.7727/wimj.2014.192

Source DB:  PubMed          Journal:  West Indian Med J        ISSN: 0043-3144            Impact factor:   0.171


  20 in total

Review 1.  Nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

2.  Aminotransferase and gamma-glutamyltranspeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome.

Authors:  G Marchesini; S Avagnina; E G Barantani; A M Ciccarone; F Corica; E Dall'Aglio; R Dalle Grave; P S Morpurgo; F Tomasi; E Vitacolonna
Journal:  J Endocrinol Invest       Date:  2005-04       Impact factor: 4.256

3.  Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease.

Authors:  F Angelico; M Del Ben; R Conti; S Francioso; K Feole; S Fiorello; M G Cavallo; B Zalunardo; F Lirussi; C Alessandri; F Violi
Journal:  J Clin Endocrinol Metab       Date:  2004-12-14       Impact factor: 5.958

4.  Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study.

Authors:  Roger K Schindhelm; Jacqueline M Dekker; Giel Nijpels; Lex M Bouter; Coen D A Stehouwer; Robert J Heine; Michaela Diamant
Journal:  Atherosclerosis       Date:  2006-05-08       Impact factor: 5.162

5.  Change of serum albumin and risk of cardiovascular disease and all-cause mortality: Longitudinal Aging Study Amsterdam.

Authors:  B W M Schalk; M Visser; M A Bremmer; B W J H Penninx; L M Bouter; D J H Deeg
Journal:  Am J Epidemiol       Date:  2006-09-15       Impact factor: 4.897

6.  The association of alanine transaminase with aging, frailty, and mortality.

Authors:  David G Le Couteur; Fiona M Blyth; Helen M Creasey; David J Handelsman; Vasi Naganathan; Philip N Sambrook; Markus J Seibel; Louise M Waite; Robert G Cumming
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2010-05-24       Impact factor: 6.053

7.  Low alanine aminotransferase activity in older people is associated with greater long-term mortality.

Authors:  Eran Elinav; Zvi Ackerman; Yoram Maaravi; Iddo Z Ben-Dov; Eliana Ein-Mor; Jochanan Stessman
Journal:  J Am Geriatr Soc       Date:  2006-11       Impact factor: 5.562

8.  Alanine aminotransferase and gamma-glutamyl transferase are associated with the metabolic syndrome but not with angiographically determined coronary atherosclerosis.

Authors:  Christoph H Saely; Alexander Vonbank; Philipp Rein; Magdalena Woess; Stefan Beer; Stefan Aczel; Vlado Jankovic; Christian Boehnel; Lorenz Risch; Heinz Drexel
Journal:  Clin Chim Acta       Date:  2008-07-29       Impact factor: 3.786

9.  Prediction of coronary atherosclerotic disease with liver transaminase level.

Authors:  Peyman Adibi; Masoumeh Sadeghi; Majid Mahsa; Golnaz Rozati; Masood Mohseni
Journal:  Liver Int       Date:  2007-09       Impact factor: 5.828

10.  The prevalence and etiology of elevated aminotransferase levels in the United States.

Authors:  Jeanne M Clark; Frederick L Brancati; Anna Mae Diehl
Journal:  Am J Gastroenterol       Date:  2003-05       Impact factor: 10.864

View more
  3 in total

1.  Factor Analysis of Metabolic Syndrome and Its Relationship with the Risk of Cardiovascular Disease in Ethnic Populations in Rural Xinjiang, China.

Authors:  Yu Ren; Bin Wei; Yanpeng Song; Heng Guo; Xianghui Zhang; Xinping Wang; Yizhong Yan; Jiaolong Ma; Kui Wang; Mulatibieke Keerman; Jingyu Zhang; Rulin Ma; Jia He; Shuxia Guo
Journal:  Int J Gen Med       Date:  2021-08-10

2.  Oxidative Stress Status and Liver Markers in Coronary Heart Disease.

Authors:  Mostafa Cheraghi; Hassan Ahmadvand; Ali Maleki; Esmaeel Babaeenezhad; Salman Shakiba; Fatemeh Hassanzadeh
Journal:  Rep Biochem Mol Biol       Date:  2019-04

3.  Resveratrol protects against atherosclerosis by downregulating the PI3K/AKT/mTOR signaling pathway in atherosclerosis model mice.

Authors:  Wuguang Ji; Jing Sun; Zonghua Hu; Bo Sun
Journal:  Exp Ther Med       Date:  2022-04-27       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.